Reliable markers for both renal cell carcinoma (RCC) and transitional cell carcinoma of the bladder (TCC) are lacking

Hegele, A.

Hofmann, R.

Kosche, B.

Kropf, J.

English

PubMed

Reliable markers for both renal cell carcinoma (RCC) and transitional cell carcinoma of the bladder (TCC) are lacking.During tumor progression and invasion components of extracellular matrix (ECM) are degraded and parts of these different components are detectable in plasma. Cellular fibronectin (cFN) represents a well characterized ECM protein. In contrast to fibronectin in plasma produced by hepatocytes (FN) cFN has a total extra domain sequence and occurs in much smaller amounts in the circulation. The aim of our study was to evaluate cFN as a marker and to determine its possible role in clinical staging of TCC and RCC.Blood samples were collected from 30 patients before they underwent transurethral resection of the bladder because of newly diagnosed TCC. Additionally samples were collected from 69 patients with RCC before therapy. Sixty patients with non-malignant urological disorders were recruited as control group. Determination of cFN in plasma was performed by using a highly sensitive time-resolved fluorescence immunoassay (TRFIA).The control group had median cFN plasma levels of 437 ng/ml. Patients suffering from TCC or RCC showed significantly higher cFN levels. In patients with muscle invasive TCC significant higher cFN levels (p < 0.05) could be demonstrated compared to non-muscle invasive TCC. Similar results were found in RCC with significant elevated cFN levels in metastatic RCC (p < 0.005) compared to localized stage of disease. No differences were found concerning tumor grading in both malignancies.In the face of significant elevated cFN levels in TCC and RCC our data underline the important role of cFN. For future investigations the elevated cFN levels in locally progressed and metastastic disease, indicating a clinically useful tool for preoperative staging and postoperative monitoring, are of high interest

A. Hegele

R. Hofmann

B. Kosche

J. Kropf

Directory of Open Access Journals

Biomarker Insights

Evaluation of Cellular Fibronectin Plasma Levels as a Useful Staging Tool in Different Stages of Transitional Cell Carcinoma of the Bladder and Renal Cell Carcinoma

Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects.

Autocrine over expression of ﬁ bronectin by human transitional carcinoma cells impairs bacillus Calmette-Guerin adherence and signaling.

Biochemical and molecular markers in renal cell carcinoma: an update and future prospects.

Cellular ﬁ bronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA

Cellular ﬁ bronectin in patients with transitional cell carcinoma of the bladder.

Cellular ﬁ bronectin in serum and plasma: a potential new tumour marker?

Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.

Degradation of ﬁ bronectin ﬁ brils by matrilysin and characterization of the degradation products.

Diagnosis and management of superﬁ cial bladder cancer.

Differences in chemotaxis to ﬁ bronectin in weakly and highly metastatic tumor cells.

Differential inhibition of renal cancer cell invasion mediated by ﬁ bronectin, collagen IV and laminin.

Elevated levels and fragmented nature of cellular ﬁ bronectin in the plasma of gastrointestinal and head and neck cancer patients.

Evaluation of two new urinary tumor markers: bladder tumor ﬁ bronectin and cytokeratin 18 for the diagnosis of bladder cancer.

Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice.

Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev.,

Fibronectin enhances healing of excised wounds in rats.

Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy.

Fibronectins: multifunctional modular glycoproteins.

Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.

Hepatocellular carcinomas show abnormal expression of ﬁ bronectin protein.

High frequency of serum DNA alterations in renal cell carcinoma detected by ﬂ uorescent microsatellite analysis.

Increased plasma ﬁ bronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus.

Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation to recurrence.

Integrins: regulators of tissue function and cancer progression.

P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol.,

Plasma ﬁ bronectin concentration: a risk factor for arterial thrombosis?

Plasma levels of cellular ﬁ bronectin in patients with localized and metastatic renal cell carcinoma.

Prognostic value of oncofetal ﬁ bronectin isoforms in renal cell carcinomas (RCC) and adenomas.

Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases.

Role of ﬁ bronectin assembly in platelet thrombus formation.

Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.

Signiﬁ cance of tissue laminin P(1) elastase and ﬁ bronectin levels in transitional cell carcinoma of the bladder.

Systemic therapy for renal cell carcinoma.

TGF-beta1 in patients with renal cell carcinoma.

The Medical Treatment of metastatic renal cell cancer.

Time-resolved immunoﬂ uorometric assays with measurement of a europium chelate in solution: application for sensitive determination of ﬁ bronectin.

TNM Klassiﬁ kation maligner Tumoren.

Transformed human cells release different ﬁ bronectin variants than do normal cells.

Two sensitive time-resolved ﬂ uoroimmunoassays for cellular ﬁ bronectin.

Urinary ﬁ bronectin levels in patients treated with intravesical bacillus Calmette-Guerin for superﬁ cial bladder cancer.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2717843

Evaluation of Cellular Fibronectin Plasma Levels as a Useful Staging Tool in Different Stages of Transitional Cell Carcinoma of the Bladder and Renal Cell Carcinoma

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals